| Completed | 3 | 870 | Europe, Canada, Japan, US, RoW | Dabrafenib, GSK2118436, Trametinib, GSK1120212, Placebos | Novartis Pharmaceuticals | Melanoma | 06/17 | 07/23 | | |
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS |
|
|
| Not yet recruiting | 3 | 960 | Europe | CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE | INSERM, Institut National du Cancer (INCa) | Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 569 | Europe, Canada, Japan, US, RoW | Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib | Novartis Pharmaceuticals | Melanoma | 08/20 | 08/24 | | |
NCT04940052: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer |
|
|
| Active, not recruiting | 3 | 153 | Canada, US, RoW | Dabrafenib, Trametinib, Trametinib placebo, Dabrafenib placebo | Novartis Pharmaceuticals | Differentiated Thyroid Cancer | 05/27 | 06/27 | | |
